Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer
Overview
Pierre Fabre Laboratories announced today that the European Commission (EC) has approved BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. The approval is based on the results from the Phase II PHAROS trial, a global, open-label, multicentre, non-randomised trial to determine the efficacy and safety of BRAFTOVI® + MEKTOVI® in treatment-naïve and previously treated patients with BRAFV600E mutant metastatic NSCLC.[1]
Words from Pierre Fabre Laboratories
- "We are pleased to be able to extend the treatment of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) to adult patients with advanced NSCLC with a BRAFV600E mutation in Europe"" said Eric Ducournau, Chief Executive Officer of Pierre Fabre Laboratories.
- "There are currently limited targeted treatment options for BRAFV600E mutant NSCLC patients, so this approval is a significant milestone as BRAFTOVI® + MEKTOVI® will give patients the option of an additional effective targeted therapy.""
About Phase II PHAROS Trial
- The EC decision, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on 25 July, is based on the results from the Phase II PHAROS trial.
- At primary analysis (cut-off date: September 22, 2022), the primary endpoint of the trial (objective response rate [ORR] determined by independent radiology review [IRR]) was met.
- In the treatment-naïve population (n=59), the ORR was 75% (95% CI: 62, 85), including 15% complete responses (CRs) and 59% partial responses (PRs).
- Updated results with an additional 10-month follow-up showed that 64% of patients maintained a response for at least 12 months, with a median duration of response (mDOR) per IRR of 40 months (95% CI: 23.1, not estimable [NE]).
